OCLASSEN PHARMACEUTICALS
More informations about "Oclassen Pharmaceuticals"
Organization | Oclassen
Oclassen Report issue. For profit Phase 2. Founded: San Rafael CA United States ... Organization Overview. First Clinical Trial. 1999 NCT00000981. First Marketed Drug. None ...See details»
Oclassen Pharmaceuticals - PitchBook
Oclassen Pharmaceuticals General Information Description. Developer of therapeutics in the fields of dermatology and sexually transmitted diseases. The company offers dermatology …See details»
Organization | Oclassen - CDEK
Oclassen Report issue. For profit Phase 2. Founded: San Rafael CA United States ... Organization Overview. First Clinical Trial. 1999 NCT00000981. First Marketed Drug. None ...See details»
Oclassen Pharmaceuticals - Products, Competitors, Financials, …
Oclassen Pharmaceuticals was founded in 1985. Where is Oclassen Pharmaceuticals's headquarters? Oclassen Pharmaceuticals's headquarters is located at 100 Pelican Way, San …See details»
Oclassen Pharmaceuticals Inc - Company Profile and News
Oclassen Pharmaceuticals, Inc. develops and markets specialty prescription pharmaceuticals for the treatment of infectious and skin diseases, with an initial focus on dermatology and urology. …See details»
Oclassen Pharmaceuticals, Inc.: Drug pipelines, Patents, Clinical ...
Explore Oclassen Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Oclassen Pharmaceuticals: Drug pipelines, Patents, Clinical trials ...
Jul 3, 2023 Explore Oclassen Pharmaceuticals with its drug pipeline, therapeutic area, technology platform, 2 clinical trials. Data. Feature. Plans. Sign Up for Free. Request Demo. …See details»
Oclassen Pharmaceuticals :: Medtech Insight
Oclassen's clinical studies are scheduled to begin within six months. Granted exclusive worldwide license from Memorial Sloan-Kettering to develop and market two fluorinated pyramidine …See details»
Oclassen Pharmaceuticals Stock Price, Funding, Valuation, Revenue ...
Feb 27, 1997 See Oclassen Pharmaceuticals funding rounds, investors, investments, exits and more. Evaluate their financials based on Oclassen Pharmaceuticals's post-money valuation …See details»
IN-LICENSING DEVELOPER OCLASSEN FILES IPO - BioWorld
Apr 6, 1992 Oclassen Pharmaceuticals Inc., which in-licenses drugs fordevelopment, has filed for an initial public offering of 2.5million shares of common stock with a proposed price range …See details»
Oclassen Pharmaceuticals - Crunchbase
Organization. Oclassen Pharmaceuticals . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. Similar Companies. Edit Similar Companies Section. Companies …See details»
Oclassen Pharmaceuticals - CB Insights
Explore {Oclassen Pharmaceuticals's key management people. Discover current leadership team members including founders, CEO, other executives and board directors. Oclassen …See details»
Verrica Pharmaceuticals Announces Passing of Board of Directors …
Nov 19, 2019 Prior, he founded Oclassen Pharmaceuticals, which was sold to Watson Laboratories in 1997. About Verrica Pharmaceuticals Inc. Verrica is a medical dermatology …See details»
Glenn Oclassen - Richmond, California, United States - LinkedIn
View Glenn Oclassen’s profile on LinkedIn, a professional community of 1 billion members. ... Oclassen Pharmaceuticals, Inc. 1985 - 1991 6 years. President and Chief Operating Officer ...See details»
Patents Assigned to Oclassen Pharmaceuticals, Inc.
Dec 23, 1992 Assignee: Oclassen Pharmaceuticals, Inc. Inventors: Dennis W. Adair, Kenneth A. Smiles, Dannie H. King Diagnostic kit for the detection of atypical epithelia. Patent number: …See details»
5 Oclassen Clinical Trial R89-001-01 - National Center for ...
This study was originally conceived in July 1989 to evaluate the effects of fiacitabine (FIAC), administered orally, for the treatment of cytomegalovirus (CMV) infection in human …See details»
Verrica Pharmaceuticals Announces Passing of Board of Directors …
Mr. Oclassen joined the Verrica Board of Directors in December, 2015. He was formerly the President and Chief Executive Officer, and a director, of Transcept Pharmaceuticals . Prior, he …See details»
GLENN A. OCLASSEN SR. - Verrica Pharmaceuticals
Mr. Oclassen served as a member of Verrica’s Board of Directors from December 2015 until his sudden passing in November 2019. He was a renowned pioneer in the dermatology industry, …See details»
Verrica Pharmaceuticals Announces Passing of Board of ... - BioSpace
Nov 19, 2019 Mr. Oclassen joined the Verrica Board of Directors in December, 2015. He was formerly the President and Chief Executive Officer, and a director, of Transcept …See details»